Screener
Agios Pharmaceuticals AGIO EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Agios Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
FAQ
- What is Agios Pharmaceuticals's EBITDA margin?
- Agios Pharmaceuticals (AGIO) reported EBITDA margin of -461.3% in Q2 2026.
- How has Agios Pharmaceuticals's EBITDA margin changed year-over-year?
- Agios Pharmaceuticals's EBITDA margin increased by 58.7% year-over-year, from -1,116.3% to -461.3%.
- What is the long-term trend for Agios Pharmaceuticals's EBITDA margin?
- Over 4 years (2020 to 2025), Agios Pharmaceuticals's EBITDA margin has grown at a 54.8% compound annual growth rate (CAGR), from -150.7% to -864.3%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Agios Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude